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Objective: To evaluate the efﬁ  cacy and tolerability of OptiveTM, a new dry eye product 
containing sodium carboxymethylcellulose (0.5%) and glycerol (0.9%), in patients with kera-
toconjunctivitis sicca (KCS).
Methods: This was a non-interventional and observational study including patients with dry eye 
who required a change of medication or were naïve to dry eye treatment (N = 5,277). Disease 
severity, tear break-up time (TBUT), tolerability, and change in clinical symptoms were recorded 
at baseline and at ﬁ  nal visit (2 to 4 weeks after ﬁ  rst treatment).
Results: The severity of KCS was mild in 18.6%, moderate in 59.9%, and severe in 21.5% 
of patients based on physicians’ assessment. TBUT was measured in 4,338 patients before 
switching to or initiating therapy with Optive and at ﬁ  nal visit. Baseline measurement of mean 
TBUT was 7.7 ± 3.9 seconds. This value increased to 10.0 ± 4.7 seconds at ﬁ  nal visit. Most 
patients (85.4%) reported improvement in local comfort. The majority (75.1%) of patients felt 
an improvement in symptoms after changing their treatment. Two percent of patients reported 
adverse events, and 0.4% were treatment-related.
Conclusions: Optive was well tolerated and improved the symptoms of dry eye after 2 to 
4 weeks.
Keywords: keratoconjunctivitis sicca, dry eye, sodium carboxymethylcellulose, glycerol, 
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Introduction
Keratoconjunctivitis sicca (KCS), or dry eye, is an eye disease characterized by dryness 
of the cornea and conjunctiva.1,2 Dry eye is usually a chronic disease, affecting more 
than 10% of the population worldwide. In particular, it is more common among women 
and people  65 years old.2,3 Dry eye is a multifactorial disease and is accompanied by 
increased osmolarity of the tear ﬁ  lm and inﬂ  ammation of ocular surface.1 Symptoms 
of dry eye vary among patients, and most commonly they include itching, grittiness, 
burning, sensitivity to bright light, foreign-body sensation, irritation, pain, blurred 
vision, and contact lens intolerance. In severe cases, dry eye disease can also lead to 
permanent visual impairment.4,5 Clinical signs of dry eye also vary among patients 
depending on the speciﬁ  c cause of the disease and include decreased tear ﬁ  lm stability 
as measured by tear break-up time (TBUT).5 Patients with severe KCS may lose the 
ability to tear in response to neural stimulation,6–8 and are prone to sight-threatening 
corneal infection and ulceration.2
The symptoms of KCS can be managed and complications can be prevented by the 
use of artiﬁ  cial tears and lubricating gels that restore normal tear ﬁ  lm.9,10 In general, 
artiﬁ  cial tears moisturize the eye surface by simply increasing the water content of 
the tear ﬁ  lm or by preventing tear evaporation. Osmoprotection, however, is a new Clinical Ophthalmology 2009:3 34
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approach to treating dry eye by providing protection against 
hypertonicity below the corneal surface via hydrating the 
epithelial surface. Evidence suggests that the combination of 
sodium carboxymethylcellulose (0.5%) and glycerol (0.9%), 
Optive™ (Allergan Inc., Irvine, CA, USA), not only treats 
the tear ﬁ  lm but also offers osmoprotection.11 The effects 
of Optive are long-lasting, beneﬁ  ting patients with dry eye 
symptoms. The purpose of the present study was to evaluate 
efﬁ  cacy and tolerability of Optive in a broad population of 
patients with KCS in a real life setting.
Methods
Study design
This study was a multicenter, non-interventional, observa-
tional, open-label study conducted in Germany. Data collection 
was initiated in September 2007, and was completed in January 
2008. Eight hundred thirty-ﬁ  ve participating ophthalmologists 
provided anonymous patient data using a standardized data-
collection instrument. German law does not require the collec-
tion of informed consent from patients in non-interventional 
studies.
Patient selection and symptom 
measurements
All patients included in the analysis were diagnosed with dry 
eye symptoms ranging from mild to severe. These patients 
were either naïve to treatment with any dry eye medication, 
or were using only 1 artiﬁ  cial tear product at the time of initial 
assessment. At the initial assessment, patients received or were 
switched to Optive treatment, depending on if they were naïve 
to treatment or had been using an artiﬁ  cial tear, respectively. 
Patient demographics, baseline characteristics (TBUT and 
severity of dry eye), type of prior treatments, and the reason 
for changing the KCS treatment were recorded. Adverse 
events and efﬁ  cacy outcomes were measured and recorded 
by physicians at the ﬁ  nal exam (2–4 weeks after the initial 
treatment). Efﬁ  cacy endpoints were changes in clinical signs 
and symptoms, local comfort, TBUT, and the assessment of 
satisfaction with Optive. Local comfort was measured by a 
5-point scale ranging from “comfort was markedly improved” 
to “comfort was worse”. The rating was determined both by 
physician and patient and was described as the Optive experi-
ence versus previous therapy. TBUT was measured using a 
sterile ﬂ  uorescein paper diluted with a nonpreserved, balanced 
salt solution. Statistical analyses of changes in TBUT from 
baseline to ﬁ  nal exam across 3 disease severity categories 
were done via t-tests for paired samples.
Prior dry eye treatments
This study included analyses of patients who were using the 
most widely used artiﬁ  cial tears in Germany prior to study 
entry: Systane® (Alcon Pharma GmbH, Freiburg/Breisgau, 
Germany), Hylo-Comod® (Ursapharm Arzneimittel GmbH, 
Saarbrucken, Germany), Lacophtal® (Dr Winzer Pharma 
GmbH, Berlin, Germany). The major active ingredients in 
Systane®, Hylo-Comod®, and Lacophtal® were hydroxypropyl-
guar, hyaluronic acid; and povidone, respectively. All other 
patients using other artiﬁ  cial tears were analyzed together and 
grouped as “Other”. An additional group included patients who 
were naïve to dry eye treatment (“Naïve” group).
Results
Patient disposition and baseline 
characteristics
Of the initial dataset collected (N = 14,012 patients with dry 
eye) 5,277 patients fulﬁ  lled the selection criteria. As shown 
in Table 1, the majority of the patients were female and over 
60 years old. The lack of efﬁ  cacy of the prior treatments or 
the expectancy for a higher efﬁ  cacy with the new treatment in 
relieving dry eye symptoms was the most commonly reported 
reason for switching to Optive (68.6%). The severity of KCS 
was moderate in 3,162 (59.9%) patients (Table 1).
Table 1 Patient baseline characteristics
All patients N = 5,277 n (%)
Age
   30 years 209 (4.0)
   30 to  60 years 1,953 (37.0)
   60 years 3,007 (57.0)
 N/Aa 108 (2.0)
Gender
 Female 3,733  (70.7)
 Male 1,398  (26.5)
 N/A 146  (2.8)
Reason to change medicationb
 Efﬁ  cacy Comfort 3,621 (68.6)
 Safety 483  (9.2)
  Other or Multiple Reasons 150 (2.8)
Severity of dry eye 1,023 (19.4)
 Mild 983  (18.6)
 Moderate 3,162  (59.9)
 Severe 1,132  (21.5)
aN/A: not applicable due to missing information.
bReasons refer to pre-treatments or, in case of the naïve group, to the expectations 
for the new treatment.Clinical Ophthalmology 2009:3 35
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Prior KCS therapy
Prior to switching to Optive, patients with KCS used a variety 
of other artiﬁ  cial tear products (n = 66) or were naïve to dry 
eye treatments. Among the most common treatment choices 
were Systane® (n = 396; 7.5%), Hylo-Comod® (n = 367; 
7.0%), and Lacophtal® (n = 305; 5.8%). Four and a half 
percent of patients (n = 237) were naïve to treatment. The 
remaining 75.3% of the patients (n = 3972) used 1 of the other 
63 different artiﬁ  cial tears prior to study entry.
At baseline, disease severity varied in patients using 
different artiﬁ  cial tear products prior to study entry. In the 
Hylo-comod® group, severe dry eye was more frequent 
(29.2%), and mild dry eye was less frequent (12.8%) 
compared with all the other treatment groups, including the 
Naïve group. On the other hand, in the Lacophtal® treated 
group, mild dry eye was more frequent (25.9%) and severe 
dry eye was less frequent (12.5%) compared with other 
groups that used artiﬁ  cial tears prior to study enrollment. 
In the Naïve group, mild dry eye was much more frequent 
(42.6%) and severe dry eye was much less frequent (8.0%) 
than in any other groups.
Signs and symptoms of dry eye and local 
comfort with Optive
At the ﬁ  nal visit, 3963 (75.1%) patients of 5,277 patients 
reported improvement in clinical signs and symptoms 
(Figure 1). In particular, 68.9% (n = 253), 78.5% (n = 311), 
83.0% (n = 253), 75.1% (n = 2,983), and 69.6% (n = 165) 
of patients showed improvement in the Hylo-Comod®, 
Systane®, Lacophtal®, Other, and Naïve group, respec-
tively. Only a few patients (n = 136, 2.6%) reported 
worsening of the symptoms. Figure 2 illustrates that the 
majority of all 5,277 patients (85.4%) rated local comfort 
as an improvement after using Optive for 2 to 4 weeks. 
Speciﬁ  cally, 80.1% (n = 294), 84.6% (n = 335), 90.8% 
(n = 277), 85.1% (n = 3,381), and 92.0% (n = 218) of 
patients reported local comfort improvement in the 
Hylo-Comod®, Systane®, Lacophtal®, Other, and Naïve 
group, respectively.
TBUT
Figure 3 (top panel) illustrates the TBUT across 7 time 
categories for all patients. At baseline, the highest number of 
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patients had a TBUT of  6 to  8 seconds, which increased 
to  10 to  12 seconds after 2 to 4 weeks of using Optive. 
In particular, as shown in Figure 3 (bottom panel), TBUT 
signiﬁ  cantly increased from baseline to ﬁ  nal assessment in all 
3 disease severity categories (p   0.001). Table 2 summarizes 
the change in the mean TBUT from baseline to ﬁ  nal assessment 
across all prior treatments used before study entry. Within 
2 to 4 weeks, TBUT increased in 29.9% of 4,338 patients, 
indicating a robust improvement in the clinical sign of KCS.
Patients satisfaction with Optive
As shown in Figure 4, most patients (n = 4,797, 90.9%) 
were somewhat to very satisfied with using Optive. In 
detail, 86.9% (n = 319), 90.4% (n = 358), 94.1% (n = 287), 
90.7% (n = 3,603), and 97.0% (n = 230) of patients were 
satisﬁ  ed with the new therapy in the Hylo-Comod®, Systane®, 
Lacophtal®, Other, and Naïve groups, respectively.
Adverse events
Of 5,277 patients, 107 (2.0%) reported adverse events (AEs), 
none of which was considered serious. Only 20 of the AEs 
(0.4% of all patients) were identiﬁ  ed as treatment-related. 
The most commonly reported adverse events were eye 
irritation (n = 53; 1%), ocular hyperaemia (n = 12; 0.2%), 
sensation of foreign body (n = 8; 0.2%), blurred vision (n = 7; 
0.1%), and drug intolerance (n = 6; 0.1%).
Discussion
In the present study, therapy with Optive greatly improved the 
signs and symptoms of KCS in the vast majority of patients 
within 4 weeks. The dual action of Optive is likely the reason 
that Optive improved signs and symptoms of KCS in our 
study. Signs and symptoms of dry eye worsened in only a 
few cases. The vast majority of patients were very satisﬁ  ed 
or at least somewhat satisﬁ  ed with the new product, and 
the local comfort it provided was rated excellent. Patients 
valued the comfort of Optive as much better or at least 
somewhat better compared to their previous dry eye therapy. 
In accordance with these observations, the clinical sign of 
KCS (TBUT) was also improved signiﬁ  cantly in all stages 
of the disease (mild, moderate, and severe).
Optive contains sodium carboxymethylcellulose 
and glycerol, which lubricate the tear film at the eye 
surface and also promote the growth of epithelial cells 
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to provide osmoprotection.11 The tear ﬁ  lm may become 
damaged under hypertonic stress. Restoring physiologic 
osmolarity is an important goal in KCS treatment to avoid 
serious complication, such as sight-threatening corneal 
infection.12 A number of different products are available for 
dry eye treatment, including various polymers and numerous 
products with diverse viscosities and with or without 
preservative formulations.13 However, these products are not 
known to possess osmoprotective properties, and therefore 
likely provide only lubrication and do not protect epithelial 
cells against hypertonic stress.
The formulations of the artiﬁ  cial tear products play key roles 
in their efﬁ  cacy in treating KCS. In particular, in patients who 
used Hylo-comod®, which is a preservative-free formulation, 
severe dry eye was more frequent at baseline compared with 
other treatment groups. In the Lacophtal® group, severe dry 
eye was less frequent at baseline compared to other groups 
that had prior artiﬁ  cial tear therapy, which, in part, might be 
due to the low viscosity of this product. The active ingredients 
in Optive are sodium carboxymethylcellulose, which is used 
in several artiﬁ  cial tears and is an effective lubricant, and 
glycerol, which is a non-blurring and long-lasting moisturizer. 
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Figure 3 Tear break-up time (TBUT) for all patients. Top panel illustrates the change in TBUT from baseline to ﬁ  nal visit after switching to Optive across 7 time categories ( 0 to 
 4,  4 to  6,  6 to  8,  8 to  10,  10 to  12,  12 to  15, and  15 seconds). Bottom panel illustrates the mean TBUT ± standard deviation (seconds) from baseline to 
ﬁ  nal visit across the categories of dry eye disease severity, to which patients were assigned at initial assessment. Asterisk indicates statistical signiﬁ  cance (p   0.001).
Table 2 Tear break-up time at baseline and at ﬁ  nal assessment
Hylo-Comod®
n = 288
Systane®
n = 333
Lacophtal®
n = 245
Other 
n = 3,302
Naïve 
n = 170
All patients 
N = 4,338
Baseline TBUT a 
Mean ± SDb 
(Min, Max)
7.1 ± 3.8 
(0.4, 24.0)
8.1 ± 4.1 
(0.3, 30.0)
8.3 ± 3.5 
(0.4, 19.0)
7.7 ± 4.0 
(0.2, 36.0)
7.8 ± 2.9 
(2.0, 20.0)
7.7 ± 3.9 
(0.2, 36.0)
Final TBUT 
Mean ± SD 
(Min, Max)
9.5 ± 4.4 
(0.4, 25.5)
10.1 ± 4.8 
(0.3, 45.0)
10.8 ± 4.0 
(0.1, 25.0)
10.0 ± 4.8 
(0.1, 44.0)
9.5 ± 3.7 
(3.0, 22.0)
10.0 ± 4.7 
(0.1, 45.0)
Change in 
Mean TBUT 
(%)
2.4 
(33.8)
2.0 
(24.7)
2.5 
(30.1)
2.3 
(29.9) 
1.7 
(21.8)
2.3 
(29.9)
aTear break-up time, measured in seconds.
bStandard deviation.Clinical Ophthalmology 2009:3 38
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Sodium carboxymethylcellulose is an anionic water soluble 
polymer, which binds to the cell surface and aids in reducing 
water loss.11 Glycerol restores the lost cellular volume14 and 
protects cells, but does not increase viscosity that could 
contribute to blur. Optive also includes a preservative, 
PURITE®, which is gentle to the ocular surface and has 
an excellent safety record.15 The safety and tolerability of 
PURITE® has been also established in a study of 62 patients 
with mild to moderate dry eye who were treated with 0.5% 
carboxymethylcellulose that was preserved with PURITE® 
(Refresh® tears) 4 to 8 times a day for 4 weeks.16 The 
characteristics of Optive formulation suggest that it would 
be efﬁ  cient in restoring physiologic osmolarity of the tear 
ﬁ  lm with minimal side-effects. As anticipated, Optive was 
well tolerated and efﬁ  cient in this clinical study. Given the 
excellent efﬁ  cacy and tolerability of Optive in the present 
study, a longer-term treatment with this formulation may 
result in further improvements.
Conclusion
In this observational study, the use of Optive was effective 
and well tolerated in patients with dry eye.
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